Commentary: Liquid Biopsy for Average-Risk Colorectal Cancer Screening
— Abstract
The American Gastroenterological Association convened a workshop to summarize the evidence on emerging blood tests for CRC screening. This paper reports those findings and provides consensus statements from the workshop's expert panel.
— Media Mentions
- CRC Screening in Primary Care: The Blood Test Option
- Liquid Biopsy for Colorectal Cancer Appears Promising But Still Lacks Robust Efficacy
- FDA Approves First Blood Test for Colorectal Cancer
- Blood Test for CRC Screening Lags Behind Other Options in Cost-Effectiveness Study
- What if colon cancer screening didn't involve poop?
- Liquid Biopsy for Colorectal Cancer Appears Promising But Still Lacks Robust Efficacy
- Liquid Biopsy for CRC Screening May Not Be Ready for Prime Time
— Impact Stats
— Research Streams
— Cite
@article{LIEBERMAN2024,
title = {Commentary: Liquid Biopsy for Average-Risk Colorectal Cancer Screening},
journal = {Clinical Gastroenterology and Hepatology},
year = {2024},
issn = {1542-3565},
doi = {10.1016/j.cgh.2024.01.034},
month = may,
url = {https://www.sciencedirect.com/science/article/pii/S1542356524001629},
author = {David A. Lieberman and Aasma Shaukat and Folasade P. May and John M. Carethers and Iris Lansdorp-Vogelaar and Uri Ladabaum and Timothy R. Church and Anjelica Davis and Chyke A. Doubeni and John M. Inadomi and Richard C. Wender and Pedro {Nascimento de Lima} and Rosita {van den Puttelaar}}
}